Tafamidis
Tafamidis
Tafamidis (pronounced ta-fa-mi-dis) is a medication used in the treatment of transthyretin-mediated amyloidosis (ATTR), a rare, progressive, and fatal disease.
Etymology
The name "Tafamidis" is derived from the drug's chemical structure. It is a benzoxazole derivative, and its full chemical name is "2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid".
Usage
Tafamidis is used to treat a specific type of amyloidosis known as transthyretin-mediated amyloidosis. This condition is characterized by the buildup of abnormal protein deposits, known as amyloid fibrils, in various tissues and organs. Tafamidis works by stabilizing the transthyretin protein, preventing it from misfolding and forming these harmful deposits.
Related Terms
- Amyloidosis: A group of diseases in which abnormal protein, known as amyloid fibrils, builds up in tissue.
- Transthyretin: A protein that carries the thyroid hormone thyroxine (T4) and retinol-binding protein bound to retinol.
- Benzoxazole: A type of organic compound and a heterocyclic compound consisting of a benzene-fused oxazole ring structure.
Side Effects
Common side effects of Tafamidis include urinary tract infections, vaginal infections, and diarrhea. More serious side effects may include heart failure, irregular heartbeat, and fainting.
See Also
External links
- Medical encyclopedia article on Tafamidis
- Wikipedia's article - Tafamidis
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski